Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service DBS & VNS cases in California: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 17% on average (103 state-years, 2020–2024): small markets swing, so treat it as rough.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 17 | 1,187 | 48% |
| 2020 | 13 | 988 | 50% |
| 2021 | 15 | 1,006 | 52% |
| 2022 | 17 | 1,167 | 53% |
| 2023 | 18 | 1,150 | 55% |
| 2024 | 18 | 1,061 | 56% |
| 2025 from claims | – | 1,043 957–1,103 | 56% |
| 2026 forecast | – | 1,061 934–1,225 | 56% |
| 2027 forecast | – | 1,074 919–1,280 | 56% |
| 2028 forecast | – | 1,088 908–1,332 | 56% |
| 2029 forecast | – | 1,101 900–1,381 | 57% |
| 2030 forecast | – | 1,115 893–1,429 | 57% |
Deep brain and vagus nerve stimulator implants. Professional codes (what the surgeon bills): CPT 61863, 61867, 61885, 61886, 64568; the hospital bills MS-DRG 040, 041, 042.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 79% of the cases CMS names in California; 11 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 35% inpatient hospital, 65% hospital outpatient.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Washington | 6 | 357−1.8%/yr | −1.8%/yr | 0.5 | 0% | 290 in 2030−3.1%/yr |
| Arizona | 4 | 305−10%/yr | −10%/yr | 0.4 | 0% | 540 in 2030+9.8%/yr |
| Colorado | 5 | 282−2.4%/yr | −2.4%/yr | 0.6 | 14% | 540 in 2030+12%/yr |
| Montana | 1 | 133−4.9%/yr | −4.9%/yr | 0.7 | 0% | 140 in 2030+1.3%/yr |
| Oregon | 2 | 124−13%/yr | −13%/yr | 0.3 | 0% | 140 in 2030+1.9%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Aneurysm & intracranial embolization | 48 | 1,774+17%/yr | +17%/yr | 0.51.2× | 0% | 3,530 in 2030+12%/yr |
| Stroke thrombectomy | 46 | 1,384+6.8%/yr | +6.8%/yr | 0.41.1× | 0% | 1,290 in 2030−1.1%/yr |
| CSF shunts | 11 | 827+0.6%/yr | +0.6%/yr | 0.21.5× | 0% | 910 in 2030+1.5%/yr |
DBS & VNS in every state, and its device makers · Every procedure market in California · Every state · Compare with Washington
Johnson & Johnson MedTech leads with 33% of company spending on these surgeons in 2025, −1 pts on 2024.
In 2025, 8 companies reported engagement with California’s surgeons worth $956K in consulting, speaking, meals and travel tied to these products, about $53K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 56 clearances and approvals in the category, 2 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.